Preclinical cardiovascular safety assessment of pharmacology-toxicology relationship for a set of novel kinase inhibitors
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cardiovascular toxicity is one of the more common causes of attrition in preclinical and clinical drug development. Preclinical cardiovascular safety assessment involves numerous in vitro and in vivo endpoints which are being continually reviewed and improved to lower the incidence of cardiovascular toxicity that manifests only after the initiation of clinical trials. An example of notable preclinical toxicity is necrosis in the papillary muscle of the left ventricle in dogs that is induced by exaggerated pharmacological effects of vasodilators or positive inotropic/vasodilating off-target drug effects. Two distinct, small-molecule inhibitors that target an intracellular kinase, Compound A and Compound B, were profiled in 2-week dose-range finding and 4-week toxicity studies. Serum cardiac troponin (cTnI) was evaluated after a single dose and after 2-week and 4-week repeat dose studies with each kinase inhibitor. Acute effects on hemodynamic (heart rate, blood pressures, left ventricular contractility) and electrocardiographic (QTcV, PR, QRS intervals) endpoints by each inhibitor were assessed in an anesthetized dog cardiovascular model. Cardiovascular degeneration/necrosis with and without fibrosis was observed in dogs and correlated to increases in serum cTnI in repeat-dose toxicity studies. At the same doses used in toxicologic assessments, both kinase inhibitors produced sustained increases in heart rate, left ventricular contractility, and cardiac output, and decreases in mean arterial pressure. Cardiac pathology findings associated with these 2 kinase inhibitors were accompanied not only by cardiac troponin elevations but also associated with hemodynamic changes, highlighting the importance of the link of the physiologic-toxicologic interplay in cardiovascular safety assessment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“reflecting their known sensitivity to hematologic and cardiovascular toxicities and underscoring their utility in evaluating related safety risks in preclinical studies (Clark and Steger-Hartmann, 2018; Koshman et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Koshman et al., 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801
Toward a broader view of mechanisms of drug cardiotoxicity
Mamoshina, P., Rodríguez, B., & Bueno‐Orovio, A. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100216 · Cited by 167
Today’s Challenges to De-Risk and Predict Drug Safety in Human “Mind-the-Gap”
Weaver, R. J., & Valentin, J.-P. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfy270 · Cited by 119
Potential functional and pathological side effects related to off-target pharmacological activity
Lynch, J. J., Vleet, T. R. V., Mittelstadt, S. W., & Blomme, E. A. G. (2017) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2017.02.020 · Cited by 102
Self-citationCardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches
Lamore, S. D., Kohnken, R. A., Peters, M. F., & Kolaja, K. L. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00387 · Cited by 82
Self-citationCardiotoxicity of Vasodilators and Positive Inotropic/Vasodilating Drugs in Dogs: An Overview
Dogterom, P., Zbinden, G., & Reznik, G. K. (1992) · Critical Reviews in Toxicology · doi:10.3109/10408449209145324 · Cited by 66
Berridge, B. R., Pettit, S. D., Walker, D. B., Jaffe, A. S., Schultze, A. E., Herman, E. H., Reagan, W. J., Lipshultz, S. E., Apple, F. S., & York, M. J. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.04.020 · Cited by 63
Spontaneous Cardiomyopathy in Young Sprague-Dawley Rats
Chanut, F. J.-A., Kimbrough, C. L., Hailey, R., Berridge, B. R., Hughes‐Earle, A., Davies, R., Roland, K., Stokes, A. H., Casartelli, A., York, M. J., et al. (2013) · Toxicologic Pathology · doi:10.1177/0192623313478692 · Cited by 43
A Comparative Study of Minoxidil-Induced Myocardial Lesions in Beagle Dogs and Miniature Swine
Herman, E. H., Ferrans, V. J., Young, R. S. K., & Balázs, T. (1989) · Toxicologic Pathology · doi:10.1177/019262338901700114 · Cited by 43
Spontaneous and Induced Arterial Disease in the Dog: Pathology and Pathogenesis
Detweiler, D. K. (1989) · Toxicologic Pathology · doi:10.1177/019262338901700105 · Cited by 42
Cited by
Liu, X., & Fan, F. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1731947 · Cited by 4
“%) and “vascular disorders” (11.4%), reflecting their known sensitivity to hematologic and cardiovascular toxicities and underscoring their utility in evaluating related safety risks in preclinical studies (Clark and Steger-Hartmann, 2018; Koshman et al., 2024).”
InfluentialLiu, X., & Fan, F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.29.702667
Metadata
- Authors
- Koshman, Y. E., Kohnken, R., Logan, M. R., Mittelstadt, S. W., & Foley, C. M.
- Affiliations
- AbbVie (United States) (US)
- Corresponding author
- Koshman, Yevgeniya E
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-01-08
- Volume
- 198
- Issue
- 2
- Pages
- 316-327
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W4390857395
- Cited by
- 2
- References
- 24
- Citations by year
- 2026: 2
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Toxicological Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Keywords
- cardiotoxicity, kinase inhibitors, preclinical safety, cardiac troponin I, left ventricular contractility, hemodynamic effects, QTc prolongation, electrocardiographic changes, positive inotropic effect, myocardial fibrosis, canine model
- MeSH terms
- Animals, Cardiovascular System, Dogs, Heart Rate, Hemodynamics, Myocardial Contraction, Necrosis, Troponin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.